Cover Image

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.

<h4>Background</h4>To date, there is no specific literature available on the determinants for therapeutic failure (TF) with meglumine antimoniate (MA) in Northwestern-Argentina. This study aimed to identify epidemiological, clinical, and treatment-related factors that could be involved i...

Full description

Saved in:

Bibliographic Details
Main Authors:	María F García-Bustos (Author), Gabriela González-Prieto (Author), Alberto E Paniz-Mondolfi (Author), Cecilia Parodi (Author), Josefina Beckar (Author), Sibila Monroig (Author), Federico Ramos (Author), María C Mora (Author), Lourdes A Delgado-Noguera (Author), Yoshihisa Hashiguchi (Author), Daniela Jaime (Author), Sonia Moreno (Author), Luisa Ruiz-Morales (Author), César G Lemir (Author), Alejandra Barrio (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019)

identificación por PS-PCR de especies de Leishmania y su correlación con características clínicas, epidemiológicas y terapéuticas en Salta, Argentina
by: Alejandra, Barrio, et al.
Published: (2009)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016)

Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.
by: Cristian Valencia, et al.
Published: (2012)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
by: Mohamad Javad Yazdanpanah, et al.
Published: (2011)

Acute erythroid toxicity in visceral leishmaniasis: A rare complication of antimonial therapy
by: Sharma Sunita, et al.
Published: (2008)

Leishmaniose cutânea com desfecho fatal durante tratamento com antimonial pentavalente American cutaneous leishmaniasis with fatal outcome during pentavalent antimoniate treatment
by: Meiri Vanderlei Nogueira de Lima, et al.
Published: (2007)

Treatment failure of pentavalent antimonial therapy for human visceral leishmaniasis: a meta-analysis
by: Caitlin M Jones, et al.
Published: (2019)

Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?
by: Meghan R Perry, et al.
Published: (2011)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
by: Jamile Lago, et al.
Published: (2023)

The effect of oral miltefosine in treatment of antimoniate resistant anthroponotic cutaneous leishmaniasis: An uncontrolled clinical trial.
by: Masoumeh Tayyebi, et al.
Published: (2021)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
by: Brandon A Berger, et al.
Published: (2017)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
by: Jamile Lago, et al.
Published: (2023)

The Immunology of a Healing Response in Cutaneous Leishmaniasis Treated with Localized Heat or Systemic Antimonial Therapy.
by: Ines Lakhal-Naouar, et al.
Published: (2015)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
by: Jairo E Perez-Franco, et al.
Published: (2016)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
by: Sílvio Alencar Marques, et al.
Published: (2019)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024)

Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review
by: Taisa Rocha Navasconi Berbert, et al.
Published: (2018)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
by: Jamile Lago, et al.
Published: (2023)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
by: Mohammad Reza Aflatoonian, et al.
Published: (2019)

Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
by: Olga Lucía Fernández, et al.
Published: (2024)

Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.
by: Anette Stauch, et al.
Published: (2012)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
by: Nayara C Brito, et al.
Published: (2019)

Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
by: Meghan R Perry, et al.
Published: (2015)

Cost-effectiveness of chagas disease vector control strategies in Northwestern Argentina.
by: Gonzalo M Vazquez-Prokopec, et al.
Published: (2009)

PCR in the investigation of canine American tegumentary leishmaniasis in northwestern Paraná State, Brazil
by: Velasquez Leonardo Garcia, et al.
Published: (2006)

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.
by: Cesar Miranda-Verastegui, et al.
Published: (2009)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
by: Maria Del Mar Castro, et al.
Published: (2017)

Exploring a tristhione scorpionate ligand as a suitable chelator for the theranostic pair antimony-119 and antimony-117
by: Lorraine Gaenaelle Gé, et al.
Published: (2024)

Characterization and Stability of the Antimony-Quercetin Complex
by: Valcilaine Teixeira Barbosa, et al.
Published: (2019)

Hantavirus pulmonary syndrome outbreaks associated with climate variability in Northwestern Argentina, 1997-2017.
by: Ignacio Ferro, et al.
Published: (2020)

Spatial heterogeneity and risk maps of community infestation by Triatoma infestans in rural northwestern Argentina.
by: Gonzalo M Vazquez-Prokopec, et al.
Published: (2012)

Melatonin Alleviates Antimony Toxicity by Regulating the Antioxidant Response and Reducing Antimony Accumulation in <i>Oryza sativa</i> L.
by: Yutan Chu, et al.
Published: (2023)

Modeling potential risk areas of Orthohantavirus transmission in Northwestern Argentina using an ecological niche approach
by: Walter R. López, et al.
Published: (2023)

Leishmania antimony resistance/ susceptibility in Algerian foci
by: Eddaikra N, et al.
Published: (2017)

Sustainable production of radionuclidically pure antimony-119
by: Aeli P. Olson, et al.
Published: (2024)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
by: Carla Oliveira-Ribeiro, et al.
Published: (2021)

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug
by: Alberto E Paniz-Mondolfi, et al.
Published: (2008)

Key source habitats and potential dispersal of triatoma infestans populations in Northwestern Argentina: implications for vector control.
by: Ricardo E Gürtler, et al.
Published: (2014)